ESMO WCGC 2013 Report – OS though not PFS superior for FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in mCRC patients: Findings from FIRE-3
Dominik Modest, University Hospital, Grosshadern, Munch, Germany. Overall survival (OS) in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) who received first-line treatment with FOLFIRI plus… read more.